Pfizer and Biontech dose first participants in the U.S. as part of global COVID-19 MRNA vaccine development program

Pfizer

5 May 2020 - Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021.

Pfizer and BioNTech announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. 

The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Vaccine , Clinical trial , COVID-19